Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 18/20 | 0.54 |
| ▸ | FABP3 | P05413 | 1/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17311170 | 0.97 | P2RX7 (0.57) | P2RX7FABP3FABP4FABP5HRH3 | |
| SCHEMBL17310964 | 0.83 | P2RX7 (0.64) | P2RX7 | |
| SCHEMBL17310957 | 0.83 | P2RX7 (0.59) | P2RX7 | |
| SCHEMBL17311006 | 0.83 | P2RX7 (0.64) | P2RX7 | |
| SCHEMBL17310967 | 0.83 | P2RX7 (0.64) | P2RX7 | |
| SCHEMBL17311085 | 0.82 | P2RX7 (0.50) | P2RX7HRH3 | |
| SCHEMBL17311182 | 0.82 | P2RX7 (0.52) | P2RX7 | |
| SCHEMBL17311007 | 0.82 | P2RX7 (0.52) | P2RX7 | |
| SCHEMBL17311002 | 0.81 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL17311126 | 0.80 | P2RX7 (0.57) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573907-B | Quinoline derivatives and their use for neurodegenerative diseases | 默克专利有限公司 | 2020-09-08 | — | — | CN | disclosed |
| EP-3152192-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | Merck Patent GmbH (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-20160296509-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-10-13 | — | — | US | disclosed |
| US-9399623-B2 | Quinoline derivatives and their use in neurodegenerative diseases | MERCK PATENT GMBH (DE) | 2016-07-26 | — | — | US | disclosed |
| US-20150353497-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | US | disclosed |
| WO-2015187905-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353497-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885FABP3 3550/4885FABP4 4501/4885 |
| US-20160296509-A1 | NOVEL QUINOLINE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885FABP3 3550/4885FABP4 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.